OBJECTIVEdNew-onset diabetes mellitus (DM) in elderly patients is associated with increased risk of diabetes complications and mortality. It is unknown whether glycemic control in this population influences the mortality risk.
T he incidence of diabetes mellitus (DM) increases with age. The high rate of occurrence of DM in the elderly population can be explained by age-related changes in the carbohydrate metabolism (1,2) but mainly by adverse lifestyle factors (3, 4) .
The natural history and outcome of new-onset DM in the elderly is not clear, due to scarce and conflicting data.
A Chinese study suggests that DM diagnosed in older age is milder and associated with less frequent microvascular complications compared with DM diagnosed at younger age (5) . Some studies found higher cardiovascular and all-cause mortality rates in the elderly with newonset DM, compared with nondiabetic elderly subjects (6) (7) (8) (9) . However, another study found excess of mortality only in elderly females with new-onset DM but not in males (10) .
No data exist regarding the influence of glycemic control on the morbidity and mortality of elderly patients with newonset DM. Previous studies did not consider the influence of other cardiovascular risk factors or the use of hypoglycemic agents on the morbidity and mortality. As a consequence, there are no clinical guidelines specific for this group of patients (11, 12) .
The aim of this retrospective observational cohort study was to evaluate the association between glycated hemoglobin (HbA 1c ) levels and all-cause mortality and coronary revascularization procedures in elderly patients with new-onset DM.
RESEARCH DESIGN AND METHODS

Study population
The cohort included residents of the Sharon-Shomron District, Israel, who were medically insured by Clalit Health Services (CHS), the largest health maintenance organization in Israel. CHS insures .50% of the district's population, which is mostly urban and includes both Jews and Arabs. All medical information obtained at the primary care clinics is recorded in the CHS computerized database and can be accessed at the level of the individual patient. Each family physician is responsible for routinely updating the computerized medical records during each patient visit and after any hospital admission. The database includes a list of all diagnoses, demographic data, laboratory values, medications, and medical procedures. This database was the source for our study. We included patients who were 65 years of age or older and had at least two blood glucose values of 126 mg/dL and above during the same year. All of the subjects included in the study had available HbA 1c levels. We excluded from the analysis those who, in the year preceding the inclusion, had blood glucose values $126 mg/dL, had HbA 1c $6.5% (48 mmol/mol), and/or purchased oral glucoselowering medications or insulin. Subjects who had died during the inclusion year were excluded from the cohort. Patients were followed for 7 years or until they underwent a coronary revascularization procedure or died. We obtained data about purchasing oral antihyperglycemic medications, insulin, and statins. Drug compliance was considered consistent if the patient purchased the monthly dose of the drug at least six times per year, during at least 4 of the 7 follow-up years.
Study design
Study end points
The outcome measures were all-cause mortality and documentation of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery during the follow-up period.
Ethical considerations
The local institutional ethics committee approval was given on December 2011. In accordance with Ministry of Health regulations, the institutional ethics committee did not require written informed consent, because the data were anonymously collected from the computerized medical files, with no participation by the patients.
Statistical analysis
The baseline clinical characteristics of the four patient groups were compared using ANOVA test for continuous variables and x 2 test for nonparametric variables. Cox proportional hazards regression model analysis was used to estimate hazard ratios (HRs) and 95% CIs for all-cause mortality and coronary revascularization (PCI or CABG) according to the four HbA 1c groups. This analysis was adjusted for age, sex, BMI, systolic and diastolic blood pressure, previous IHD, previous CRF, current smoking, hypoglycemic medication use, statin use, and LDL-c. KaplanMeier survival curve was plotted for all-cause mortality, comparing the four groups according to HbA 1c levels. Statistical analysis was performed with the use of SPSS statistical software for windows version 20.0.
RESULTSdTwenty-one thousand eight hundred and fifty-five patients met the inclusion criteria. Fifteen thousand five hundred and fifty were excluded because of blood glucose values .126 mg/dL, HbA 1c $6.5% (48 mmol/mol), or use of antidiabetic medications before the inclusion. Another 1,141 subjects who died during the inclusion year were excluded. Five thousand one hundred and sixty-four subjects with a mean age of 77.4 6 7.5 years were available for analysis.
Only 2,994 of them had HbA 1c levels measured during the study period. The mean age for subjects with measured HbA 1c levels was 75.6 years, compared with 79.8 years for subjects without HbA 1c measurement (P , 0.0001). The average glucose value was 131.4 6 28.5 mg/dL, compared with 122.7 6 28.9 mg/dL for subjects without HbA 1c measurement (P , 0.0001). In the group of subjects with measured HbA 1c levels, the all-cause mortality rate during the follow-up years was 40% and revascularization rate 9.5%, compared with 69% mortality and 3.3% revascularization in subjects with no HbA 1c measurement (P , 0.0001).
Out of the 2,994 subjects who were available for analysis, 1,448 (48.36%) were males. The subjects were stratified by their mean HbA 1c level during the follow-up period. Table 1 shows baseline characteristics of the four groups. HbA 1c levels correlated with the fasting blood glucose and triglycerides levels. The LDL-c level was significantly higher in the fourth group. Smoking rates and BMI were significantly lower in the lowest HbA 1c group. Other cardiovascular risk factors, including HDL-c levels and systolic blood pressure, were similar between the four groups. Only 11.2% of the patients in the lowest HbA 1c group acquired hypoglycemic medications. With higher HbA 1c levels, the use of hypoglycemic medications was more prevalent: 29.8, 39.2, and 37.4% in the second, third, and fourth groups, respectively (P , 0.001). The majority of the treated patients used oral hypoglycemic medications (11.1, 29.8, 37.3, and 35.3% respectively; P , 0.001). Only 3% of the patients in the fourth group were treated with insulin alone or in combination with oral hypoglycemic medications. The rate of insulin treatment in the other groups was even lower (0.1, 0.2, and 2.2% in the first, second, and third group, respectively; P , 0.001). Statin use was highest in the second group (51%) and lowest in the fourth group (30%).
HbA 1c level and mortality
A total of 1,173 subjects died during the follow-up years. All-cause mortality rates were 41, 32, 36, and 46% in the four groups (Table 2) . A multivariate model, adjusted for age, sex, previous IHD, previous CRF, use of statin and hypoglycemic medications, current smoking, BMI, systolic and diastolic blood pressure, and LDL-c, was conducted. An HbA 1c level .7.5% (58 mmol/mol) was associated with a significantly increased mortality rate, compared with the 6.5-6.99% (48-52 mmol/mol) HbA 1c group, which had the lowest mortality rate (adjusted HR 1.4 [95% CI 1.1-1.6], P , 0.01). In subjects with HbA 1c 7-7.49% (53-57 mmol/mol), mortality rates were higher, compared with the lowest mortality group (adjusted HR 1.2 [0.99-1.5], P = 0.052), but did not reach statistical significance (Table 2) . Because of the broad range of HbA 1c in the fourth group, we divided these subjects into two subgroups: HbA 1c 7.5-8.5% (58-69 nmol/mol) and HbA 1c .8.5% (.69 nmol/mol). There was a higher mortality rate in subjects with HbA 1c .8.5% (69 nmol/mol) compared with subjects with HbA 1c 7.5-8.5% (58-69 nmol/mol) levels, but this difference was not statistically significant (51.4 vs. 43%, P = 0.098).
The average survival time was 5.8, 6.1, 5.8, and 5.4 years in the four groups. Figure 1 depicts the Kaplan-Meier survival curves according to HbA 1c levels. The lowest survival rates were found in patients with HbA 1c .7.5% (58 mmol/mol), and the highest survival rates in patients with HbA 1c 6.5-6.99% (48-52 mmol/mol). The lines separated after 1 year of followup and remained separated during the entire follow-up period.
HbA 1c levels and coronary revascularization A total of 285 subjects underwent coronary revascularization procedures (PCI or CABG) during the follow-up years. Coronary intervention rates were 9.7, 11, 9.5, and 7% in the four groups (Table 3) . A multivariate model, adjusted for age, sex, previous IHD, previous PVD, previous CRF, use of statin and hypoglycemic medications, current smoking, BMI, systolic and diastolic blood pressure, total cholesterol, HDL-c, LDL-c, and triglycerides, was conducted. The revascularization rate was highest in subjects with HbA 1c 6.5-6.99% (48-52 mmol/mol) and significantly higher compared with the HbA 1c $7.5% (58 mmol/mol) group, which had the lowest revascularization rate (adjusted HR 1.6 [95% CI 1.01-2.4], P , 0.05). Because of the broad range of HbA 1c in the fourth group, we divided these subjects into two subgroups: HbA 1c 7.5-8.5% (58-69 nmol/mol) and HbA 1c .8.5% (.69 nmol/mol). There was a lower revascularization rate in subjects with HbA 1c .8.5% (69 nmol/mol) compared with subjects with HbA 1c 7.5-8.5% (58-69 nmol/mol) levels, but this difference was not statistically significant (5.1 vs. 8.1%, P = 0.26).
CONCLUSIONSdEvidence on the optimal glycemic control for the subgroup of patients with new-onset DM in older age (65 years of age and above) is limited. The few studies that compared elderly subjects with new-onset DM to nondiabetic patients demonstrated shortterm elevation in all-cause and cardiovascular mortality (6-10) and long-term elevation of microvascular and macrovascular complications (7) . None of these studies checked the association of glycemic control with mortality or diabetes complications. As a consequence, the guidelines of the international diabetic and geriatric associations do not deal with this special population (11, 12) .
In this large observational cohort study, we have demonstrated that HbA 1c level $7.5% (58 mmol/mol) during 7 years follow-up in elderly patients with new-onset DM is associated with significantly increased all-cause mortality compared with lower HbA 1c levels. Within this group of patients, HBA 1c .8.5% (69 nmol/mol) was associated with an even higher mortality rate, although this difference did not reach statistical significance. The lowest mortality rate was found in subjects with HbA 1c 6.5-6.99% (48-52 mmol/mol). Data regarding the cause of death and prevalence of hypoglycemia were not available.
It is important to emphasize that the subjects with the highest HbA 1c levels had an unfavorable cardiovascular risk factors profile, including higher LDL-c and triglyceride level, lower HDL-c, higher smoking rate, and higher diastolic blood pressure. In addition, the use of statins was lowest in subjects with HbA 1c $7.5% (58 mmol/mol) and highest in subjects with HbA 1c 6.5-6.99%. Nevertheless, the difference in mortality rates remained statistically significant after multivariate analysis. Kaplan-Meier survival plots revealed lower survival rates in this group of patients.
The association between glycemic control, diabetes complications, and mortality has been investigated for many years. A large retrospective cohort study of patients older than 50 years with longstanding type 2 DM and intensive hypoglycemic treatment demonstrated a U-shaped pattern of risk association between HbA 1c levels and mortality. HbA 1c of ;7.5% (58 mmol/mol) was associated with the lowest all-cause mortality rate (13) . The difference in mortality patterns between our finding and the aforementioned study underscores the need to differentially treat elderly patients with new-onset DM and elderly patients with long-standing disease.
The group with the lowest HbA 1c had a higher mortality rate compared with the 6.5-6.99% group. This finding is in accordance with other study findings, which demonstrated higher mortality in elderly patients with very tight glycemic control (13, 14) . In our study, the same pattern was found in the elderly with new-onset DM. However, the former studies included subjects with longstanding DM who were intensively treated with various hypoglycemic medications, whereas in our cohort, only 11.2% of these subjects used hypoglycemic medications. We assume that the mildly elevated glucose of the subjects in the first group of our cohort may reflect other detrimental disease and is not directly related to DM or its treatment.
The second main finding of our study is that coronary revascularization rates were significantly higher in subjects with 
